Bioanalysis of bevacizumab and infliximab by high-temperature reversed-phase liquid chromatography with fluorescence detection after immunoaffinity magnetic purification |
| |
| Authors: | Kenichiro Todoroki Tatsuki Nakano Yasuhiro Eda Kaname Ohyama Hideki Hayashi Daiki Tsuji Jun Zhe Min Koichi Inoue Naoki Iwamoto Atsushi Kawakami Yukitaka Ueki Kunihiko Itoh Toshimasa Toyo'oka |
| |
| Affiliation: | 1. Laboratory of Analytical and Bio-Analytical Chemistry, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan;2. Department of Pharmacy Practice, Graduate School of Biomedical Sciences, Nagasaki University, Japan;3. Laboratory of Pharmacy Practice and Social Science, Gifu Pharmaceutical University, Gifu, Japan;4. Laboratory of Clinical Pharmacology and Genetics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan;5. Laboratory of Clinical and Analytical Chemistry, College of Pharmaceutical Sciences, Ritsumeikan University, Japan;6. Unit of Translational Medicine, Department of Immunology and Rheumatology, Graduate School of Biomedical Sciences, Nagasaki University, Japan;g Sasebo Chuo Hospital, Japan |
| |
| Abstract: | This study presents two simple and rapid methods for the quantification of therapeutic mAbs based on LC. Two mAbs (bevacizumab and infliximab) in plasma samples were purified using magnetic beads immobilized with a commercially-available idiotype antibody for each mAb. Purified mAbs were separated with HT-RPLC and detected with their native fluorescence. Using immunoaffinity beads, each mAb was selectively purified and detected as a single peak in the chromatogram. The HT-RPLC achieved good separation for the mAbs with sharp peaks within 20 min. The calibration curves of the two mAbs ranged from 1 to 20 μg mL−1 (bevacizumab) and 1–10 μg mL−1 (infliximab), and they had strong correlation coefficients (r2 > 0.998). The LOD of bevacizumab and infliximab was 0.07 and 0.15 μg mL−1, and the LLOQ of bevacizumab and infliximab was 0.12 and 0.25 μg mL−1, respectively. Thus, the sensitivities were sufficient for clinical analysis. Immunoaffinity purification with HT-RPLC produced a selective and accurate bioanalysis without an LC-MS/MS instrument. Both methods could become general-purpose analytical methods and complement the results obtained with conventional LBA. |
| |
| Keywords: | Therapeutic antibodies High-temperature reversed-phase liquid chromatography Immunoaffinity purification Bevacizumab Infliximab |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
